Attainable predictive biomarkers for tumor reaction to mTOR inhibitors, as have been described in glioblastoma, breast and prostate cancer cells, will be the differential expression of mTOR pathway proteins, PTEN, AKT, and S6.[1] As a result, this info is based on preclinical assays, based upon in vitro cultured tumor mobile https://guyw852mru6.wikigop.com/user